What is Eli Lilly and Company?
The pharmaceutical giant behind Mounjaro and Zepbound — powering medicine's GLP-1 revolution
- Category
- Pharmaceuticals / Biotechnology
- Headquarters
- Indianapolis, Indiana, USA
- Founded
- May 10, 1876
- Employees
- ~50,000 worldwide (Dec 2025)
- Revenue (FY2025)
- $65.2 billion (+45% YoY)
- Market Cap
- ~$1.04 trillion (June 2026, NYSE: LLY)
What is Eli Lilly and Company?
Eli Lilly and Company is a global pharmaceutical leader headquartered in Indianapolis, Indiana, founded in 1876 and now the world's largest pharmaceutical company by revenue. The company discovers, develops, manufactures, and commercializes medicines across diabetes, obesity, oncology, immunology, and neuroscience — best known today for the blockbuster GLP-1 therapies Mounjaro (tirzepatide for type 2 diabetes) and Zepbound (tirzepatide for obesity). In FY2025, Lilly reported $65.2 billion in revenue, a 45% year-over-year increase, and more than 71 million patients worldwide benefited from Lilly medicines.
Eli Lilly and Company is a 150-year-old pharmaceutical enterprise that has, in the span of three years, become the defining company of the GLP-1 revolution — a therapeutic category transforming treatment for diabetes, obesity, heart failure, and sleep apnea. Lilly's GLP-1 franchise is the fastest-growing in pharmaceutical history: Mounjaro and Zepbound together generated $36.5 billion in combined 2025 sales — roughly 56% of total company revenue — and Q1 2026 saw Mounjaro alone produce $8.7 billion (up 125% YoY). The company raised its full-year 2026 revenue guidance to $82–$85 billion after a dominant Q1, which would make Lilly the first pharmaceutical company in history to exceed $80 billion in annual revenue.
Beyond its GLP-1 dominance, Lilly maintains a diversified oncology, immunology, and neuroscience portfolio that serves more than 71 million patients annually across 18+ countries. Verzenio (abemaciclib) is a leading breast cancer treatment with $4.2 billion in 2025 sales; Taltz (ixekizumab) addresses psoriasis and psoriatic arthritis; and an Alzheimer's pipeline anchored by donanemab — which received FDA Breakthrough Therapy Designation — continues to advance through late-stage development. The company's clinical pipeline has more than 25 Phase 3 trials with positive topline results, including next-generation agents retatrutide (a triple-acting incretin demonstrating up to 29% weight loss in Phase 2) and orforglipron (an oral GLP-1, FDA-approved as Foundayo in April 2026 — the first oral GLP-1 obesity drug Lilly has brought to market).
Lilly went public on the NYSE in 1952 and has a market capitalization of approximately $1.04 trillion as of June 2026, making it one of the twelve largest companies in the world by market value. The company employs approximately 50,000 people — roughly 23,500 in the US and 26,500 internationally — and operates manufacturing, research, and commercial facilities globally, including its Lilly Corporate Center headquarters campus in downtown Indianapolis.
What does Eli Lilly offer?
Lilly's portfolio spans GLP-1 metabolic therapies, oncology, immunology, and neuroscience, with a next-generation pipeline covering oral GLP-1s, triple-acting incretins, Alzheimer's disease, and cardiovascular disease.
- Mounjaro (tirzepatide)· Cardiometabolic / Diabetes
- Zepbound (tirzepatide)· Obesity / Weight Management
- Foundayo (orforglipron)· Obesity — Oral GLP-1
- Verzenio (abemaciclib)· Oncology / Breast Cancer
- Taltz (ixekizumab)· Immunology / Dermatology
- Trulicity (dulaglutide)· Cardiometabolic / Diabetes
- Humalog / Humulin (insulin lispro)· Insulin / Diabetes
- Retatrutide· Pipeline — Triple Incretin
- Donanemab· Pipeline — Alzheimer's
- Eloralintide· Pipeline — Obesity (Amylin)
- LillyDirect (D2C platform)· Direct-to-Consumer Health
How does Eli Lilly make money?
Eli Lilly generates revenue almost entirely through the development, manufacturing, and commercialization of patented prescription medicines sold to pharmacies, hospitals, pharmacy benefit managers (PBMs), and governments worldwide. The company's tirzepatide franchise now accounts for over 56% of total revenue, with Mounjaro and Zepbound leading a volume-driven growth model that is partially offset by managed care rebates and government-negotiated pricing.
The core revenue model is branded prescription drug sales at premium list prices, with net prices considerably lower after PBM rebates, copay assistance, and government discounts. Zepbound carries a US list price of approximately $1,086 per month for the 15 mg dose; through Lilly's LillyDirect D2C platform — launched in partnership with Walmart Health in 2025 — cash-pay patients can access vials at $299 per month (2.5 mg / 5 mg) or $449 per month (7.5 mg / 10 mg / 12.5 mg / 15 mg), dramatically expanding the addressable market beyond patients with insurance coverage. Mounjaro's wholesale acquisition cost is similarly priced above $1,000 per month at list, though net prices after PBM rebates and government discounts are substantially lower. In Q1 2026, volume growth of 49% for US products partially offset a 7% net price drag — illustrating the classic volume-led, price-pressured pharma growth model.
Revenue concentration has accelerated sharply: Mounjaro ($8.7B in Q1 2026, +125% YoY) and Zepbound ($4.2B in Q1 2026, +79% YoY) now account for the vast majority of Lilly's growth. The company's oncology franchise (Verzenio: $4.2B in FY2025) and immunology portfolio (Taltz) provide meaningful but slower-growing contributions. Trulicity faces biosimilar and competitive headwinds as next-generation GLP-1 therapies cannibalize older diabetes drugs, illustrating the patent-cliff risk inherent to any pharma business model. Internationally, Mounjaro's 2025 addition to China's national reimbursement list opened a massive new volume opportunity at lower net prices.
Lilly's primary growth levers for 2026 and beyond are: (1) label expansions for tirzepatide — ongoing trials in heart failure (SURMOUNT-HF), sleep apnea, kidney disease, and non-alcoholic steatohepatitis; (2) new molecular entities including retatrutide (up to 29% weight loss in Phase 2, superiority over semaglutide) and donanemab for Alzheimer's; (3) the LillyDirect platform, which enables direct-to-patient pricing that bypasses traditional PBM channels and improves net margin quality; and (4) oral GLP-1 with Foundayo (orforglipron) targeting the estimated 650 million adults with obesity who prefer a pill to an injection.
Who leads Eli Lilly?
Eli Lilly is led by Chairman and CEO David A. Ricks, who has helmed the company since 2017, alongside a 14-person Executive Committee overseeing R&D, finance, digital, manufacturing, and commercial operations. The leadership team has shepherded Lilly's transformation from a mid-size pharma to a ~$1 trillion market-cap company.
- David A. RicksChairman and Chief Executive OfficerCEO since January 2017; Chairman since June 2017Named Chief Executive Magazine's 2025 CEO of the Year. Under his leadership Lilly's revenue grew from ~$21B in 2017 to $65.2B in 2025 and market cap surpassed $1 trillion. Previously led Lilly's BioMedicines business and Lilly USA.
- Daniel M. Skovronsky, MD, PhDChief Scientific and Product Officer; President, Lilly Research LaboratoriesJoined Lilly 2010 (via Avid Radiopharmaceuticals acquisition)Oversees all R&D and global commercial product responsibility; founded Avid Radiopharmaceuticals in 2004 and served as its CEO before Lilly's acquisition. Architect of Lilly's pipeline strategy including tirzepatide and donanemab.
- Lucas MontarceExecutive Vice President and Chief Financial OfficerCFO since 2024; at Lilly since 2001Previously served as global CFO of Elanco Animal Health (Lilly's spinoff) and CFO of Lilly Research Laboratories. Oversees Lilly's capital allocation strategy during its period of peak revenue growth.
- Diogo RauExecutive Vice President and Chief Information and Digital OfficerJoined Lilly 2021Leads Lilly's global digital transformation, AWS cloud modernization, and AI-infrastructure investments including LillyDirect and the internal AI coding infrastructure platform. Previously served as Apple's VP of Information Systems.
- Kenneth Custer, PhDExecutive Vice President and President, Lilly Cardiometabolic HealthAppointed 2024/2025Oversees Lilly's highest-growth division, which includes Mounjaro, Zepbound, Foundayo (orforglipron), and retatrutide — the franchise responsible for more than 56% of FY2025 revenues and the bulk of 2026 guidance.
- Jacob Van NaardenExecutive Vice President; President, Lilly Oncology and Head of Corporate Business DevelopmentLong-tenured Lilly executiveLeads the oncology division (Verzenio) and all corporate BD/M&A activities. Oversaw 39 transactions and more than $4B in capital deployment in 2025, including partnerships with Scorpion, Verve Therapeutics, Adverum, and SiteOne.
How do you contact Eli Lilly's leadership?
Eli Lilly's verified corporate email domain is lilly.com. The most common employee email pattern confirmed across data sources is first-initial + last name (e.g., dricks@lilly.com). For verified press contact, use the published media contact b-roll@lilly.com or the investor relations team at investor.lilly.com.
dricks@lilly.comHow much funding has Eli Lilly raised?
Eli Lilly is a publicly traded company (NYSE: LLY) that has never raised venture or private equity capital. The company IPO'd on the NYSE in 1952 and has been self-financing through operating cash flows and investment-grade debt ever since, with a market capitalization of approximately $1.04 trillion as of June 2026.
Eli Lilly went public on the New York Stock Exchange in 1952, at a time when the company's revenues were growing through its polio vaccine and antibiotic franchises (vancomycin, erythromycin). For more than seven decades, Lilly financed itself entirely through operating cash flows and investment-grade bond issuances — not equity dilution. The company carries long-term debt consistent with an A-rated pharmaceutical company, used primarily to fund large bolt-on acquisitions rather than operating losses.
Key capital deployment milestones include: the acquisition of Avid Radiopharmaceuticals in 2010 (approximately $300M upfront plus milestones, bringing in Daniel Skovronsky and Alzheimer's diagnostics capabilities); the $8 billion acquisition of Loxo Oncology in 2019 (precision oncology pipeline including larotrectinib); the approximately $3.2 billion acquisition of Morphic Therapeutic in 2024 (oral integrin inhibitors for inflammatory bowel disease); and more than $4 billion in 39 transactions executed in 2025, including partnerships with Scorpion Therapeutics, Verve Therapeutics, Adverum, and SiteOne. Lilly also invested billions in manufacturing capacity expansion across Indiana, North Carolina, Germany, and Ireland to meet surging GLP-1 demand.
Lilly's market capitalization surged from roughly $250 billion in 2021 to approximately $1.04 trillion by June 2026, driven almost entirely by the commercial ramp of tirzepatide. As a public company, the most relevant capital metrics are market cap and operating cash flow rather than VC rounds. The company's full-year 2026 revenue guidance of $82–$85 billion and non-GAAP EPS guidance of $35.50–$37.00 position it as the world's largest pharmaceutical company by revenue and one of the twelve most valuable companies on earth by market capitalization.
How did Eli Lilly get here?
Eli Lilly's 150-year arc spans from a four-person drugstore in Indianapolis to a trillion-dollar pharmaceutical giant — each era defined by a transformative scientific bet, from insulin in the 1920s to GLP-1s in the 2020s.
- May 10, 1876Founded in IndianapolisColonel Eli Lilly, a Civil War veteran and pharmaceutical chemist, opens a laboratory at 15 West Pearl Street with himself, his 14-year-old son Josiah, and two employees. Sales triple by end of 1877.
- 1923World's First Commercial Insulin (Iletin)Lilly partners with University of Toronto researchers to commercialize insulin, introducing Iletin — the world's first commercially available insulin product — transforming diabetes from a death sentence to a manageable condition. This partnership defined Lilly's century-long commitment to metabolic disease.
- 1952NYSE IPO; Polio Vaccine ManufacturingLilly goes public on the New York Stock Exchange. By 1955 the company produces more than half the US supply of Jonas Salk's polio vaccine. Also introduces antibiotics erythromycin and vancomycin during this era.
- 1987Prozac ApprovedThe FDA approves Prozac (fluoxetine HCl) for clinical depression. Prozac becomes one of the best-selling drugs in history, generates billions in annual revenues, and defines Lilly's identity through the 1990s.
- 1996Humalog Approved — First Rapid-Acting Insulin AnalogueFDA approves Humalog (insulin lispro), created by swapping two amino acids in the human insulin molecule to accelerate time-action. By 2016 Humalog is Lilly's largest product by revenue.
- 2019Loxo Oncology Acquisition — $8 BillionLilly acquires Loxo Oncology for approximately $8 billion, adding a precision oncology pipeline anchored by larotrectinib and selpercatinib, and dramatically accelerating the Lilly Oncology division's targeted therapy capabilities.
- May 2022Mounjaro (tirzepatide) FDA Approved for Type 2 DiabetesThe FDA approves tirzepatide as Mounjaro for type 2 diabetes — the first dual GIP/GLP-1 receptor agonist in history. Mounjaro delivers superior glycemic control vs. semaglutide and sets the stage for the obesity approval.
- November 2023Zepbound FDA Approved for ObesityThe FDA approves tirzepatide as Zepbound for chronic weight management, delivering up to 20.9% average weight loss in the SURMOUNT-1 trial — the largest weight-loss effect ever seen in a Phase 3 trial at the time of approval. Global demand immediately outstrips supply.
- FY2025 / Early 2026$65.2B Revenue; $1T Market Cap; Foundayo ApprovedLilly reports FY2025 revenue of $65.2B (+45%), surpassing Pfizer to become the world's #1 pharma company by revenue. The FDA approves Foundayo (orforglipron) — the first oral GLP-1 for obesity — in April 2026. Full-year 2026 guidance of $82–$85B is raised following Q1 2026 revenue of $19.8B (+56% YoY).
Who are Eli Lilly's competitors?
Lilly's primary competition comes from Novo Nordisk in GLP-1/obesity (its most direct rival), and from Pfizer, AbbVie, Merck, AstraZeneca, and Amgen across oncology, immunology, and cardiometabolic markets.
- Novo NordiskLilly's most direct GLP-1 rival — Ozempic/Wegovy (semaglutide) competes head-to-head with Mounjaro/Zepbound; Novo launched the first oral obesity GLP-1 (oral Wegovy / semaglutide 25 mg) in early 2026, weeks ahead of Lilly's Foundayo.
- PfizerBroad-based pharma giant entering obesity aggressively after acquiring Metsera for up to $10B; competes with Lilly in oncology and across diversified therapeutic areas.
- AbbVieCompetes directly in immunology — Skyrizi and Rinvoq challenge Lilly's Taltz and pipeline assets; AbbVie is well-positioned for second-half-of-decade growth in immunology.
- Merck & Co.Oncology rival via Keytruda (pembrolizumab), the world's best-selling cancer drug; also competes in cardiometabolic with its own obesity and diabetes pipeline.
- AstraZenecaCompetes in oncology (Tagrisso, Imfinzi) and cardiovascular (Farxiga for diabetes/heart failure); one of the fastest-growing big pharma companies by revenue in 2025.
- AmgenCompetes in obesity (MariTide, a monthly injectable GLP-1/GIPR agonist-antagonist) and oncology biosimilars; also a rival in inflammation and bone disease where Lilly has pipeline assets.
Eli Lilly and Company — frequently asked questions
